Work

Serological Evidence of Hepatitis B Virus Vaccination Among University Students in Lafia, Nigeria

Year: 2026
Type: preprint
Study design: Observational Study
Abstract: Background Hepatitis B virus (HBV) vaccination is highly effective, yet protection is not guaranteed to be lifelong, and evidence on how long vaccine-induced immunity persists among Nigerian university students remains limited. This study assessed serological evidence of protection against HBV among vaccinated students of the Federal University of Lafia (FULAFIA) and examined the factors associated with its persistence. Methods A descriptive cross-sectional study was conducted among 120 students with a documented or self-reported history of HBV vaccination. Structured questionnaires captured demographic, vaccination, and lifestyle data, and venous blood samples were screened using an HBV rapid diagnostic test (RDT) combo panel (HBsAg, anti-HBs, HBeAg, HBeAb, HBcAb). Associations between anti-HBs status and selected variables were tested using chi-square and Fisher's exact tests (α = 0.05). Results Detectable anti-HBs was found in 51.7% (62/120) of participants; 48.3% (58/120) showed no serological evidence of protection. One participant (0.8%) was HBsAg-positive with a marker profile consistent with chronic HBeAg-negative phase infection. Time since last vaccination was the strongest correlate of protection (χ² = 56.92, df = 4, p < 0.001), with protection falling from 87.9% in those vaccinated under 5 years ago to 0.0% beyond 15 years. Age at vaccination was also significant (χ² = 39.19, df = 3, p < 0.001), whereas current age group (p = 0.272), sex (p = 0.417), and number of doses received (p = 0.052) were not. Conclusions Nearly half of vaccinated students at this Nigerian university no longer show serological evidence of protection against HBV, driven principally by time elapsed since vaccination rather than by demographic characteristics. These findings support the introduction of post-vaccination serological screening and targeted booster vaccination in university health services, and add university-level evidence to the ongoing debate over WHO's no-routine-booster guidance in high-endemicity settings. Trial registration: Not applicable.
Language: English
Subfield: Epidemiology
Field: Medicine
Open Access status: green
OpenAlex ID: W7234321076
Cites: 29
Cited by:
Related to: 10